Current Prices from Elevation Oncology, Inc. - Common stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	ELEV	USD	10.06.2025 23:40	0,38 USD	0,38 USD +1,61 %

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
0,00 %	27,72 %	11,39 %	-18,32 %	-48,42 %	-89,17 %	-96,64 %

Company Profile for Elevation Oncology, Inc. - Common stock Share

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Company Data

Name Elevation Oncology, Inc. - Common stock

Company Elevation Oncology, Inc.

Symbol ELEV

Website https://elevationoncology.com

Primary Exchange

NASDAQ

ISIN US28623U1016

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Mr. Joseph J. Ferra Jr.

Market Capitalization 22 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 888 Seventh Avenue, 10106 New York

IPO Date 2021-06-25

Ticker Symbols

Name	Symbol
NASDAQ	ELEV

More Shares

Investors who Elevation Oncology, Inc. - Common stock hold also have the following shares in their portfolio:

NINETEEN77 ENVIRONMENTAL FOCUS FUND (EU) - CLASS (USD) A-ACC 001 ETF

Vanguard Balanced Index Fund Institutional Shares ETF

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog